NEW YORK, July 17, 2026, 07:07 EDT – Shares of AtaiBeckley NASDAQ:ATAI indicate a market valuation for merger rights amounting to 14% of their face value.
AtaiBeckley Inc. NASDAQ:ATAI was priced at $7.091 ahead of Friday’s session, declining 0.8%. The share price remained 34 cents higher than Eli Lilly and Co.’s NYSE:LLY $6.75 cash offer. Nasdaq premarket volumes were active. Trading officially opens at 9:30 a.m. EDT.
On the surface, this spread reflects the pricing of one CVR, which offers three potential payments. The entitlement pays no more than $2.50 per share. The spread also incorporates closing risk and timing risk.
The CVR will not be traded and is mostly non-transferable. This does not represent a typical cash merger spread. Investors are exposed to clinical and regulatory risk for a period of four to seven years.
Lilly said on Thursday it will pay around $2.8 billion upfront, with total deal value reaching about $3.8 billion if all milestones are achieved. The companies anticipate closing the transaction in the third quarter, subject to shareholder and regulatory clearance.
The SEC filing lists the official payments underneath. The market-implied figure is based on an initial estimate with the 07:02 EDT quote.
| Measure | Per share | Timing or trigger | Market comparison |
|---|---|---|---|
| Premarket quote | $7.091 | 07:02 EDT Friday | Baseline |
| Cash at closing | $6.75 | When the merger completes | 4.8% under quote |
| Preliminary implied CVR | $0.341 | Quote minus cash | 13.6% of total possible |
| VLS-01 Phase 3 payment | $1.00 | Study begins within four years | Conditional |
| BPL-003 approval payment | $0.50 | U.S. approval and DEA rescheduling within five years | Conditional |
| VLS-01 approval payment | $1.00 | U.S. approval and DEA rescheduling within seven years | Conditional |
| Maximum package | $9.25 | Every milestone met | 30.4% over quote |
The $0.341 figure represents 13.6% of the CVR’s maximum face value. This is not an implied probability of success. Each payout is subject to distinct risks and timing conditions.
The stock ended Thursday at $7.15, rising 33.4%, with 166 million shares traded. Trading volume was 18.5 times higher than the daily average between July 6-10. The share price increased 38.3% since last Friday’s close, after falling 0.4% the previous week.
BPL-003, a synthetic 5-MeO-DMT therapy delivered intranasally, targets resistant depression. VLS-01 is administered as a buccal DMT film and is currently in Phase 2b trials.
Shares of GH Research plc (NASDAQ:GHRS), a mebufotenin peer, rose 7.9% Thursday. The company is advancing inhaled 5-MeO-DMT for treatment-resistant depression. The moderate increase signals a sector read-through rather than wholesale takeout repricing.
Jefferies analyst Andrew Tsai forecasts potential sales for BPL-003 between $1 billion and $2 billion, if late-stage trials succeed. The first data is anticipated in early 2029.
Barclays analyst Emily Field noted the deal provides “upside potential in large markets like depression.” Reuters
Investors are awaiting details on the preliminary proxy and the voting schedule. Early Friday, AtaiBeckley’s filings page listed an 8-K and a DEFA14A, but no preliminary proxy.
Voting agreements account for roughly 15% of the outstanding shares. To be approved, the deal must win a majority of all outstanding shares. As a result, the reported support block does not eliminate the risk of failing to secure enough votes.
Risks are present. Shareholders could vote down the merger, and regulatory authorities may postpone it. Clinical or regulatory milestones might not be achieved. The unlisted CVRs might have no payout. The outside date is six months, with a possible extension to nine months for some regulatory delays.
As of Friday’s close, cash still serves as the benchmark. Assets listed above represent illiquid, long-term biotech bets.
